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Abstract
Objectives: Ongoing randomized controlled screening trials for prostate
cancer have not shown a beneficial effect on prostate cancer mortality
reduction yet. A large number of observational (non-randomized) stu-
dies on prostate cancer screening have been published with contra-
dictory outcome. This paper reviews the current case-control studies.
Methods: Seven case-control studies of screening for prostate cancer
were identified in a PubMed search, published from 1991 onwards, all
conducted in North America. The screening test was either digital rectal
examination (DRE) alone or in combination with PSA.
Results: One DRE case-control study, found a significant preventive
effect, whereas two others showed no effect of DRE screening on prostate
cancer mortality nor on the occurrence of metastatic disease. Conflicting
results were also observed in the studies assessing the effect of PSA/DRE.
Only one study showed a significant 27% mortality reduction in the
White male cohort, but found no effects in Blacks. The most recent
study showed that screening with PSA/DRE was not protective in redu-
cing prostate cancer mortality.
Conclusions: Our review of the case-control studies does not indicate a
benefit of prostate cancer screening. An answer has to come from the
ERSPC trial, in Europe, and the PLCO trial, in the US, of which the
outcomes are expected in 2007–2010.
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Prostate cancer is the most commonly diagnosed
non-cutaneous cancer and the third most common
cause of death from cancer in males in the US,
estimated at 27,350 deaths in 2006 [1]. The prostate-1871-2592/$ – see front matter # 2006 European Association of Urology
Published by Elsevier B.V. All rights reserved.specific antigen (PSA) test for the early detection of
prostate cancer, introduced in late 1980’s, has
rapidly gained popularity, not only among health-
care providers and their patients, but also among the
‘‘healthy’’ male population. This increasing public
awareness and the subsequently rising use of theand European Board of Urology. doi:10.1016/j.eeus.2006.08.002
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Fig. 1 – Basic concept of the case-control study design.PSA test, as a means of early detection, demands an
answer on the question whether early detection of
prostate cancer reduces prostate cancer specific
mortality.
Currently two randomized controlled trials (RCT)
are under way, the European Randomized Study of
Screening for Prostate Cancer (ERSPC) [2] and the
Prostate Lung Colorectal and Ovary cancer screening
trials (PLCO) [3], to study the effectiveness of
screening for prostate cancer. The ERSPC was
initiated in 1993 and has approximately 205,000
men randomized in eight different centers in
Europe. The PLCO trial was also initiated in 1993
and has included approximately 74,000 men, ran-
domized to the prostate arm of the trial. Conditions
for a possible common analysis of ERSPC and PLCO
trial have been discussed [4].
The ongoing randomized trials will not produce
results for several years [5]. Furthermore, the benefit
of the RCT design may not be realized if screening in
men allocated to the control arm is widespread. This
together with the knowledge that prostate cancer
has a relatively long natural history, several case-
control studies were already performed to try
speeding up the process of answering the question
on the value of prostate cancer screening. Here we
review the results of published case-control studies
on the efficacy of prostate cancer screening.
2. Materials and methods
2.1. Search strategy
The PubMed database was searched for papers published until
April 2006, in the English language. Search query included the
terms prostate cancer (prostate carcinoma) and case-control
(case control) in title and/or abstract. For each retrieved paper,
the reference lists were checked upon relevant (accessible)
literature and the PubMed option Related Articles was
consulted.
2.2. Basic methodological concept of case-control study
It is well known that the RCT is the study design that provides
the most reliable unbiased estimates of the effect of the
intervention under study. The RCT is the preferred approach
for evaluation of cancer screening programs. In this study
design, subjects consenting to participate are randomly
allocated to either the screening group, offered screening, or
to the control group, that is not offered any screening. The
final outcome is assessed according to the intention-to-screen
principle where the rate of the cancer-specific mortality is
compared between the screening and the control group. In
absence of an RCT, e.g. screening test is already widely
disseminated [6], information on screening can also be
achieved from observational (non-randomized) designs as
cohort studies, where groups of individuals is followed up overa period of time, and from time trend analyses, which are
based on examination of (aggregated) mortality data of
populations across time. Another observational design used
to evaluate cancer screening programs is the case-control
study. Fig. 1 presents the basic concept of this study design.
In a case-control study of screening, the potential effect of
the screening test for prevention of an adverse outcome (e.g.
late stage of a disease or mortality) is examined by comparing
the exposure to the screening test between those subjects with
the adverse outcome, the cases, and those without this
outcome, the controls [7]. The evaluation of the efficacy of a
test in cancer screening focuses on reducing cancer-specific
mortality, hence, the control subject should be alive at the date
of death of the case subject and cancer-free at diagnosis of the
case subject. As the starting-point of the case-control study is
the presence of the adverse outcome in the cases, the
exposure to the screening test has to be examined retro-
spectively, i.e. the screening history of each case and his
matched control(s) has to be assessed in the period preceding
the diagnosis of the case [7,8]. The frequency of screening (ever
or never screened) is then compared between the cases and
their matched controls which gives an estimate of the strength
of the association (Odds ratio, OR), whether screening
prevents the adverse outcome (Fig. 1). Importantly, as the
screening test is often the same used for diagnostic purposes,
true screenings should be distinguished from tests done in
relation to symptoms; e.g. both digital rectal examination
(DRE) and PSA are used for screening asymptomatic men and
for examination of symptomatic subjects.
The cases and controls are selected from the same source
population (Fig. 1) and age range within which screening is
available. Any difference in screening history between cases
and controls would be due to different rates of acceptance of
the screening program (or opportunistic screening). Hence,
cases and controls may not be appropriately ‘‘representative’’
as might be the case in screening for prostate cancer. It is
known that African-Americans have a high-risk for prostate
cancer, but the frequency of PSA testing in this population is
low compared with the Whites [9].
The key advantages of a case-control study are that it is less
costly, less lengthy compared to RCT, does not require a large
number of subjects, is appropriate for studying rare conditions
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Table 1 – Description of the case-control studies on prostate cancer screening
Source population Age at entry Cases Controls Index date Screening exposure
Years N Diagnosis PCa Follow-up endpoint Na Test(s) Definition Window
A. Metastasis
Friedman et al. [19] health plan 39–95b 139 1975–1985 at diagnosis or later 139 d DRE e 3 mo–10 yr
Kopec et al [16] geographic area 40–84c 236 1 Jan 1990 8/1999–5/2002 462 d PSA f e
B. Death
Jacobsen et al. [17] geographic area g 173 <1970–1991 1976–1991 346 d DRE e 10 yr
Richert-Boe et al. [18] health plan 40–84b 150 e 1981–1990 299 d DRE f 10 yr
Weinmann et al. [13] health plan 45–84c 171 e 1992–1999 342 d PSA/DRE f 10 yr
1997–1999/2000 d f 10 yr
Weinmann et al. [14]h health plans 45–84c 608/161 e 1997–6/2001 608/321 PSA/DRE
Concato et al. [15]i medical centers 50j 501 1991–1995 1991–1999 501 d PSA/DRE f 6 mo–5 yr
Abbreviation; PCa, prostate cancer.
a Endpoint free (no metastasis or alive and prostate cancer free at diagnosis of case).
b At prostate cancer diagnosis.
c At endpoint.
d Date of diagnosis case.
e Poorly or not described/defined.
f Well or moderately described/defined.
g Not selection criterion.
h White, Black men separately.
i Nested case control study.
j PCa free as of 1 Jan 1991 & ambulatory care 1989–1990.
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the possibility of examining multiple exposures, [8]. However,
case-control studies are very susceptible to biases, and the
major bias inherent to this study design are misclassification
bias and (self-)selection bias. As mentioned above, the screen-
ing and diagnostic test are often the same. If during review of
medical records, a test performed for diagnostic purposes in a
control is erroneously assigned as screening test or a screening
test in a case is incorrectly classified as diagnostic test, this
ascertainment procedure would introduce misclassification
bias which would lead to a bias in favor of screening or against
screening, respectively [10]. Subjects attending a screening
program or seeking opportunistic screening might differ in the
risk of the disease under study, in social-economic status and in
access to the screening test. High-risk subjects often decline
participation in screening programs. These aspects confer
(self-)selection bias, affecting the frequency of screening either
in favor or against screening [7].
Although there are several methods described in order to
correct for the above-mentioned biases [11,12], the generally
regarded optimal design for the evaluation of a population-
based screening program is an RCT. With the RCT design, the
study population consists of subjects free of the disease at
start of the study, randomly divided into two groups, but
perhaps most importantly the investigators assigned the
exposure under study. Therefore, an RCT provides the
strongest evidence for causality and controls for ‘‘unknown’’
confounders.
3. Results
Only seven case-control studies of screening for
prostate cancer were identified in the PubMed
search, published from 1991 onwards, all conducted
in North America. Of these, only three studies
assessed the efficacy of either PSA alone or PSA
and DRE on prostate cancer mortality [13–15]. One
study concerned the effect of PSA screening on the
development of metastatic disease [16] and the three
remaining examined whether screening by DRE is
associated with a reduction in prostate cancer
mortality [17,18] or metastatic disease [19]. A
description of these studies is presented in Table 1.
The source population from which both cases and
controls were selected was composed of medical
registries of health-care plans and centers (Kaiser
Permanente, [13,14,18,19]; VA Outpatient Clinic
System Database, [15,20]) or defined geographical
areas (Metropolitan Toronto and surrounding coun-
ties, [16], and Olmsted County, Rochester Epidemiol-
ogy Project, [17]). The subjects were aged 39 years
and older at diagnosis of prostate cancer or at
reaching study endpoint (metastasis or death from
prostate cancer). An exception is the study by
Jacobsen et al. [17], where no age range is given,
as age was not an inclusion criterion, but prostate
cancer death in a defined time period (1976–1991).Matching of controls to cases was primarily based
on age and the date of enrollment in a health plan, a
site of ambulatory care in a medical center or an area
of residence for the studies using geographical area
as source population. The two most recent studies,
Weinmann et al. [14] and Concato et al. [15], included
the largest number of cases and matched controls
(Table 1). The index or reference date was properly
defined in all studies, as the first date of suspicion of
prostate cancer [8]. In the studies by Weinmann
et al., an additional symptoms reference date was
selected, defined as first date on which symptoms
were noted that were subsequently found to be
related to prostate cancer.
The results of the studies examining the potential
role of screening on the development of advanced
prostate cancer and those on mortality are dis-
cussed below separately.
3.1. Outcome: metastatic prostate cancer
The results of the two studies with metastasis of the
prostate as outcome are presented in Table 2A. The
study by Friedman et al. [19] was conducted in men
with prostate cancer diagnosed in the pre-PSA era
(1979–1985), hence the exposure to DRE screening
was identified through review of medical charts.
DRE in the three months prior to diagnosis were not
included in the analyses to keep the case-control
status undisclosed to the chart reviewers. Both cases
and matched controls arose from the database of a
regional health plan and were within the age group
39–95 years. The race-adjusted odds ratio (OR), up to
10 years before diagnosis, indicated no benefit
of screening in prevention of the development
of metastatic disease (OR = 0.9, 95% confidence
interval, CI, 0.5–1.7). When DRE performed for
evaluation of intestinal or rectal symptoms were
included as ‘‘screening’’, the OR became 0.7, but still
statistically not significant (95% CI, 0.4–1.4).
In contrast, Kopec et al. [16] found that PSA
screening reduced the risk of metastatic prostate
cancer by 35% (OR = 0.65, 95%CI, 0.45–0.93). This
beneficial effect was seen in men aged 45–59 years
(OR = 0.52, CI, 0.28–0.98), and to some extent in those
aged 60–84 years (OR = 0.67, 95%CI, 0.41–1.09). Some
methodological points of this study should also be
noted. The strength of the study is the effort in
differentiating between true screening and diag-
nostic PSA tests, thorough review of medical charts
for adjustment of baseline prognostic factors and a
sensitivity analysis correcting for positive/suspi-
cious DRE. However, there is a potential non-
response and information bias in this study as the
number of participants returning the mailed
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Table 2 – Adjusted odds ratios of case-control studies on prostate cancer screening with either DRE alone or PSA and DRE
PSA +/ DRE DRE alone
OR (95% CI) OR (95% CI)
A. Outcome: metastatic prostate cancer
DRE era
Friedman et al. [19] 0.9 (0.5–1.7)
0.7 (0.4–1.4)a
PSA era
Kopec et al. [16] 0.65 (0.45–0.93)
0.52 (0.28–0.98)b
0.67 (0.41–1.09)c
B. Outcome: prostate cancer mortality
DRE era
Richert-Boe et al. [18] – 0.84 (0.48–1.46)
Jacobsen et al. [17] – 0.53 (0.32–0.90)d
0.32 (0.20–0.52)e
PSA era
Weinmann et al. [13] 0.70 (0.46–1.1) 0.60 (0.38–0.93)
0.69 (0.38–1.2)f
Weinmann et al. [14]g W, 0.73 (0.55–0.97)h W, 0.65 (0.45–0.85)h
B, 1.00 (0.59–1.40) B, 0.86 (0.53–1.40)
Concato et al. [15] 1.13 (0.63–2.06)
Abbreviations: OR, odds ratio, CI, confidence interval.
a Including DREs for evaluation of intestinal or rectal symptoms.
b Age group 45–69 years.
c Age group 60–84 years.
d Any DRE in exposure window.
e Only DRE in absence of prostate cancer symptoms.
f Membership > = 10 years.
g Only screening test classified as definitely.
h Study reference date, W = white, B = black.informed consent was low and differed among cases
and controls (69% and 51%, respectively). The same
was true for the availability of medical charts (93%
and 88%, respectively). This problem is also pointed
out in an editorial by Barry [21]. In contrast to the
other case-control studies where cases and controls
are matched on age and the length of exposure
window is kept equal for the case-control pair, the
authors of this study matched only on age and
considered the difference in exposure window as a
confounding factor, which they adjusted for. It may
be possible that the adjustment for exposure time
has led to significant difference in outcome.
3.2. Outcome: prostate cancer mortality
Table 2B shows the corresponding odds ratios of the
case-control studies assessing the potential benefit
of prostate cancer screening with prostate cancer
mortality as endpoint. The two DRE case-control
studies, conducted in the pre-PSA era, showed
contradictory results, varying from a 68% significant
preventive effect (OR 0.32, 95% CI 0.20–0.52; [17]) to
no effect of DRE screening on prostate cancermortality (the odds ratio was not significantly
different from 1, OR 0.84 95%CI 0.48–1.46, [18]). In
the study by Jacobsen et al. [17], the analyses were
restricted by eliminating the first year before the
index date to exclude DREs possibly performed for
diagnostic purposes. This restriction could have
introduced misclassification bias in favor of screen-
ing, hence the reason of the significant result of this
study.
Conflicting results were found in the PSA/DRE
studies as well. In their first study, Weinmann et al.
[13] found no statistical significant effect of the
combination of PSA and DRE. However, in their
subsequent study with a larger population size [14],
a significant 27% reduction was observed, but this
concerned the White male cohort only. This effect
seemed to be attributable to DRE screening, as
analyses including only DRE revealed statistically
significant OR of 0.65 (95% CI 0.45–0.85) in Whites. In
Black men, there was no evidence that cases were
less likely to have had PSA/DRE screening than the
controls, even when DRE alone was considered.
Then again the population size was smaller than
that for the White cohort (Table 1). If the White and
e au - e b u u p d a t e s e r i e s 4 ( 2 0 0 6 ) 2 1 9 – 2 2 7224Black cohort data were analyzed jointly, most likely
the study would not have yielded a statistically
significant result.
Concato et al. [15], adjusting for race, showed no
effect of PSA/DRE screening in their nested case-
control study (OR 1.13, 95% CI 0.71–1.64). Additional
analyses including tests performed in men with BPH
symptoms or test for differential diagnosis did not
alter the outcome.
Connor et al. [22] have shown that the criteria for
selecting matched controls to cases, the choice of
the time scale of screening and the method to
measure exposure of screening in case-control
studies can considerably affect the results due to
biases introduced. The retrospective identification
of screening exposure, particularly for prostate
cancer, remains a difficult issue. In all studies
reviewed, determination of the reason of the tests
were done through review of medical records and in
the most recent PSA/DRE studies [14,15], the authors
made use of algorithms to classify the PSA and DRE
findings as definitely screening, probably screening
or diagnostic tests, accounting for BPH and its
symptoms. The study of Jacobsen et al. [17], which
assessed whether screening with DRE reduced
prostate cancer mortality, did not take examina-
tions that were performed for evaluation of BPH
symptoms into account. Screening was defined as
the absence of hematuria, bone pain and pelvic pain
at the time of DRE. However, even when the analysis
where performed with exposure being any DRE,
an adjusted OR of 0.53 (95% CI 0.32–0.90) was
observed. The importance of accurate classification
of true screening and diagnostic tests in case-
control studies of the efficacy of prostate cancer
screening have been demonstrated by several
authors [10,23–25]. If screening tests are not
properly defined, the proportion of subjects classi-
fied as screened will be distorted leading to
biased study results. Hence, the studies of Wein-
mann et al. [14] and Concato et al. [15] were likely
not biased by misclassification of the exposure.
However, the significant outcome for DRE alone
in White men in the large study of Weinmann et al.
[14] might reflect (self-)selection bias as prostate
cancer screening is opportunistic and, as mentioned
before, the rate of screening in the US is higher
among the White population.4. Discussion
A large number of observational studies on the
evidence of prostate cancer screening and mortality
reduction have been published with contradictoryoutcome [26–29]. Coldman et al. [30] observed that
high screening intensity is not associated with large
reductions in prostate cancer mortality, when
compared with geographic areas with low or
medium screening intensity. Using incidence-based
mortality rates, Chu et al. [31] demonstrated that the
decrease in mortality rates among men with distant
disease diagnosis accounted for the overall decline
in prostate cancer mortality trends in the USA. In the
non-randomized prospective Tyrol screening study
initiated in 1993, men aged 45–74 years were offered
the PSA test [28,32]. Over the period 1996–2000, the
trends in prostate cancer mortality showed that the
mortality in Tyrol was 35% lower than in the rest of
Austria.
The results of the Quebec RCT, started in 1988,
only further contributed to the controversy on
prostate cancer screening. In the two publications
of this RCT, decreases of 69% [33] and 62% [34] in the
prostate cancer mortality were reported, when
screened men were compared to unscreened men.
The proper analyses according to the intention-to
screen principle yielded relative risks of 1.06 [33]
and 1.08 [34], respectively, indicating no effect of
screening, particularly due to lack of power.
From this current review of case-control studies
we can conclude that the evidence for a beneficial
effect of prostate cancer screening on mortality
reduction is still not unambiguous. The major
limitation of the case-control studies reviewed
is the potential misclassification of the exposure,
PSA tests and DREs, particularly in presence of
other non-cancer symptoms of the prostate, and
the accuracy of the index date. The studies by
Concato et al. [15] and Weinmann et al. [14] seem
not to be weighed down by these aspects, but
there is evidence of selection bias in Weinmann’s
study as a significant result was only seen in White
men.
Decisions on population-based screening require
solid evidence of its benefits on the reduction of
cancer-specific mortality. The costs and the effects
of quality of life will be important additional
outcomes. It is clear from the studies discussed
above that observational study designs were not
able to provide the evidence needed for this
important decision. Level one evidence, i.e. from a
prospective RCT is definitely still required. Waiting
for the outcome of the two large-scaled randomized
trials [3,35] seems the only rational approach.
However, the question remains how a result of an
intention-to-screen analysis from an RCT of screen-
ing (effectiveness estimate) can be translated
to daily practice, since there is always a certain
level of non-compliance in the screening arm and
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question of the value of early detection on an
individual level (efficacy estimate) a secondary
analysis with both correction for non-compliance
and contamination is needed [36]. This type of
analysis determines the magnitude of benefit in
terms of prostate cancer risk/mortality reduction by
attending a screening program.
When non-compliance and contamination are
large in a RCT, investigators might make compar-
isons of those who actually received the interven-
tion with those who did not, similar as in the
publication of the Quebec trial [33,34]. This would
lead to large effect estimates, but is not valid, as the
randomization status is not complied with, introdu-
cing selection bias in the analyses. A method to
adjust for non-compliance and contamination in an
RCT has been developed by Cuzick et al. [36], which
in the Rotterdam section of ERSPC, will be applied
in addition to the main intention-to-screen analysis,
to give an effect estimate after adjustment for non-
compliance and contamination. A case-control
study using the ERSPC data will also be conducted
afterwards to give an impression of the magnitude
of all known biases inherent to the case-control
study on the outcome of a population-based trial.5. Conclusion
In conclusion, as for other observational studies, the
current available data from case-control studies on
the value of early detection of prostate cancer in
reducing disease specific mortality yielded incon-
clusive evidence. Hence, the presumably most
debated topic in urologic practice remains uncertain
at this time point. An answer has to come from well-
conducted RCTs, the ERSPC in Europe and the PLCO
trial in the US, of which the outcomes can be
expected in 2007–2010.
With the growing awareness of prostate cancer
screening not only among physicians, but also
among the general population, a point of concern
for these RTCs can be the generalizibility to
population level. As described above valid statistical
techniques are available to correct for this issue to
obtain a reliable estimate of the true effect of
undergoing the screening test. Until then, it is
advisable that men who wish to be screened should
be well informed of both the benefits and possible
harms (i.e. overdiagnosis, overtreatment, conse-
quences of aggressive treatment as sexual, urinary
and bowel dysfunctions) of prostate cancer screen-
ing, realizing that the major benefit on prostate
cancer mortality reduction has not been shown yet.References
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Please visit www.eu-acme.org/europeanurology
to answer these EU-ACME questions on-line. The
EU-ACME credits will then be attributed automati-
cally.1. The major drawback of the case control study
design is that:
A. It is not suitable for rare conditions.
B. The retrospective design induces susceptibil-
ity for selection and misclassification bias.
C. The intervention under study (cause) is not
applied by the investigator.
D. It is logistically inefficient.2. The strongest evidence on the effect of an
intervention on disease outcome is a RCT since
A. It has a prospective study design.
B. It is based on individual data.
C. It has an observational approach.
D. The exposure under study is applied by the
investigator.3. The term ‘index or reference date’ refers to the:
A. date of diagnosis of the case
B. date of death of the case
C. date on which the case was screened
D. date on which the control was screened
e a u - e b u u p d a t e s e r i e s 4 ( 2 0 0 6 ) 2 1 9 – 2 2 7 2274. Which of the following statements is correct in a
case-control study with prostate cancer death as
endpoint?
A. A case is a subject who was diagnosed with
prostate cancer and died from lung cancer
B. A control is a subject who was diagnosed with
prostate cancer before his matched case and
died from prostate cancer
C. A case is a subject who was diagnosed with
prostate cancer and still alive
D. A control is a subject without prostate cancer
before the date of diagnosis of his matched
case and still alive at death of this case5. Regarding the effect of screening on prostate
cancer mortality following statement is correct:
A. Case-control studies demonstrated the effec-
tivity of PSA screeningB. The Quebec RCT showed conclusive and
unbiased outcome
C. Trend analyses are useful in analyzing the
effect of screening
D. The evidence of prostate cancer screening and
mortality has yet to come from the RCTs6. The outcome of a RCT on the effectiveness of a
screening program can
A. automatically be translated to daily practice.
B. be interpreted as an efficacy estimate of the
screening program applied.
C. give an efficacy estimate after correction for
both non-compliance and contamination.
D. give a reliable estimate on the effectiveness of
the program when using an intention-to-treat
analysis.
